8 terminated. 8 Phase 1.
By phase and status
Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies OB318 capsule - Advanced Solid Malignancies Phase 1 Terminated 21 2020-08-28 2026-07-10
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Theophylline, Erlotinib - Non-small Cell Lung Cancer, Advanced Solid Malignancies Phase 1 Terminated 15 2014-09-01 2019-05-03
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. AZD1480 Daily, AZD1480 BID - Solid Tumour, Advanced Solid Malignancies Phase 1 Terminated 47 2010-11-01 2013-01-08
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours AZD4547 - Cancer, Advanced Solid Malignancies Phase 1 Terminated 95 2009-10-21 2019-03-15
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine AZD7762, gemcitabine - Cancer, Solid Tumors Phase 1 Terminated 24 2009-07-01 2011-02-07
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 AZD6918, gemcitabine, pemetrexed - Cancer,, Solid Tumors Phase 1 Terminated 75 2008-08-01 2010-12-10
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies BMS-663513 - Advanced Solid Malignancies Phase 1 Terminated 45 2007-09-01 2009-09-04
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan AZD7762, Irinotecan - Advanced Solid Tumors, Cancer Phase 1 Terminated 60 2007-05-01 2011-02-11
Narrower conditions Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (1) · Diarrhea (1) · Stomach Neoplasms (1)
Broader conditions Neoplasms (2) · Neoplasms by Site (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Signs and Symptoms (1) · Signs and Symptoms, Digestive (1)
Interventions 3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide (2) · Gemcitabine (2) · AZD4547 (1) · Erlotinib Hydrochloride (1) · Irinotecan (1) · Pemetrexed (1) · Theophylline (1) · urelumab (1)
Sponsors AstraZeneca (5) · AHS Cancer Control Alberta (1) · Bristol-Myers Squibb (1) · Oneness Biotech Co., Ltd. (1)
Countries United States (4) · Canada (2) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Top investigators Peter Langmuir, MD (2) · Becker Hewes, MD (1) · Ching-Liang Ho (1) · Donal Landers, Dr (1) · Jeffrey Infante, MD (1) · Judith Ochs, MD (1) · Kang Yoon-Koo, MD, PhD (1) · Lia Gore, MD (1) · Michael Sawyer, MD (1) · Takashi Seto, MD, PhD (1)